Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(12):1920–1926. doi: 10.1038/sj.bjc.6690621

CDKN2A gene inactivation in epithelial sporadic ovarian cancer

D Niederacher 1, H-Y Yan 1,2, H-X An 1, H G Bender 1, M W Beckmann 1
PMCID: PMC2363140  PMID: 10471040

Abstract

The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to uncontrolled cell growth. In order to determine the role of CDKN2A in the development of sporadic ovarian cancer, loss of heterozygosity at 9p21–22, homozygous deletion, mutation and methylation status of the CDKN2A gene as well as CDKN2A expression were examined in a panel of serous papillary ovarian cancer. The frequency of loss of heterozygosity (LOH) for one or more informative markers at 9p21–22 was 65% (15/23). The most common deleted region was located between interferon (IFN)-α and D9S171. Homozygous deletions and mutations of the CDKN2A gene were not found. There was no evidence of methylation in exon 1, but methylation in exon 2 of CDKN2A gene was found in 26% (6/23). Absence of CDKN2A gene expression was shown in 27% (6/22) at mRNA level and 21% (4/19) at protein level. These data suggest that the CDKN2A gene is involved in the tumorigenesis of ovarian cancer, but the mechanisms of CDKN2A gene inactivation in serous papillary ovarian cancer remains unclear. © 1999 Cancer Research Campaign

Keywords: CDKN2A gene, LOH, 9p21–22, RT-PCR, immunohistochemistry, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (123.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckmann M. W., Niederacher D., Massenkeil G., Tutschek B., Beckmann A., Schenko G., Schnürch H. G., Bender H. G. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology. 1996 Nov-Dec;53(6):441–447. doi: 10.1159/000227618. [DOI] [PubMed] [Google Scholar]
  2. Beckmann M. W., Picard F., An H. X., van Roeyen C. R., Dominik S. I., Mosny D. S., Schnürch H. G., Bender H. G., Niederacher D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer. 1996 May;73(10):1220–1226. doi: 10.1038/bjc.1996.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cairns P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J. E., Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994 Jul 15;265(5170):415–417. doi: 10.1126/science.8023167. [DOI] [PubMed] [Google Scholar]
  4. Campbell I. G., Foulkes W. D., Beynon G., Davis M., Englefield P. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995 Oct 9;63(2):222–225. doi: 10.1002/ijc.2910630213. [DOI] [PubMed] [Google Scholar]
  5. Chenevix-Trench G., Kerr J., Friedlander M., Hurst T., Sanderson B., Coglan M., Ward B., Leary J., Khoo S. K. Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet. 1994 Jul;55(1):143–149. [PMC free article] [PubMed] [Google Scholar]
  6. Cliby W., Ritland S., Hartmann L., Dodson M., Halling K. C., Keeney G., Podratz K. C., Jenkins R. B. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15;53(10 Suppl):2393–2398. [PubMed] [Google Scholar]
  7. Costello J. F., Berger M. S., Huang H. S., Cavenee W. K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996 May 15;56(10):2405–2410. [PubMed] [Google Scholar]
  8. Del Tito B. J., Jr, Poff H. E., 3rd, Novotny M. A., Cartledge D. M., Walker R. I., 2nd, Earl C. D., Bailey A. L. Automated fluorescent analysis procedure for enzymatic mutation detection. Clin Chem. 1998 Apr;44(4):731–739. [PubMed] [Google Scholar]
  9. Devlin J., Elder P. A., Gabra H., Steel C. M., Knowles M. A. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer. 1996 Feb;73(4):420–423. doi: 10.1038/bjc.1996.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dong Y., Walsh M. D., McGuckin M. A., Gabrielli B. G., Cummings M. C., Wright R. G., Hurst T., Khoo S. K., Parsons P. G. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer. 1997 Feb 20;74(1):57–63. doi: 10.1002/(sici)1097-0215(19970220)74:1<57::aid-ijc10>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  11. Eiriksdottir G., Sigurdsson A., Jonasson J. G., Agnarsson B. A., Sigurdsson H., Gudmundsson J., Bergthorsson J. T., Barkardottir R. B., Egilsson V., Ingvarsson S. Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer. 1995 Dec 20;64(6):378–382. doi: 10.1002/ijc.2910640605. [DOI] [PubMed] [Google Scholar]
  12. Fujita M., Enomoto T., Haba T., Nakashima R., Sasaki M., Yoshino K., Wada H., Buzard G. S., Matsuzaki N., Wakasa K. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 1997 Apr 22;74(2):148–155. doi: 10.1002/(sici)1097-0215(19970422)74:2<148::aid-ijc2>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  13. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  14. Gray-Bablin J., Zalvide J., Fox M. P., Knickerbocker C. J., DeCaprio J. A., Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15215–15220. doi: 10.1073/pnas.93.26.15215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hatta Y., Hirama T., Takeuchi S., Lee E., Pham E., Miller C. W., Strohmeyer T., Wilczynski S. P., Melmed S., Koeffler H. P. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol. 1995 Nov;154(5):1954–1957. [PubMed] [Google Scholar]
  16. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  17. Kishimoto Y., Sugio K., Hung J. Y., Virmani A. K., McIntire D. D., Minna J. D., Gazdar A. F. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst. 1995 Aug 16;87(16):1224–1229. doi: 10.1093/jnci/87.16.1224. [DOI] [PubMed] [Google Scholar]
  18. Lo K. W., Cheung S. T., Leung S. F., van Hasselt A., Tsang Y. S., Mak K. F., Chung Y. F., Woo J. K., Lee J. C., Huang D. P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 1996 Jun 15;56(12):2721–2725. [PubMed] [Google Scholar]
  19. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. doi: 10.1038/nm0795-686. [DOI] [PubMed] [Google Scholar]
  20. Milde-Langosch K., Ocon E., Becker G., Löning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 1998 Feb 20;79(1):61–65. doi: 10.1002/(sici)1097-0215(19980220)79:1<61::aid-ijc12>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  21. Niederacher D., Picard F., van Roeyen C., An H. X., Bender H. G., Beckmann M. W. Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer. 1997 Mar;18(3):181–192. doi: 10.1002/(sici)1098-2264(199703)18:3<181::aid-gcc5>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  22. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  23. Schultz D. C., Vanderveer L., Buetow K. H., Boente M. P., Ozols R. F., Hamilton T. C., Godwin A. K. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 1995 May 15;55(10):2150–2157. [PubMed] [Google Scholar]
  24. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  25. Shigemasa K., Hu C., West C. M., Clarke J., Parham G. P., Parmley T. H., Korourian S., Baker V. V., O'Brien T. J. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig. 1997 Mar-Apr;4(2):95–102. [PubMed] [Google Scholar]
  26. Shih Y. C., Kerr J., Liu J., Hurst T., Khoo S. K., Ward B., Wainwright B., Chenevix-Trench G. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer. 1997 Mar 4;70(5):508–511. doi: 10.1002/(sici)1097-0215(19970304)70:5<508::aid-ijc3>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  27. Spruck C. H., 3rd, Gonzalez-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumours. Nature. 1994 Jul 21;370(6486):183–184. doi: 10.1038/370183a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES